MWNA
PACB icon

Marshall Wace North America’s Pacific Biosciences PACB Stock Holding History

Marshall Wace North America’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,658
Closed -$94K – 1816
2018
Q4 		$94K Buy
+12,658
New +$80.2K ﹤0.01% 1093

Other funds holding PACB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Marshall Wace North America's PACB Position: Q1 2019 in Review

Marshall Wace North America sold out of Pacific Biosciences (PACB) in Q1 2019, closing a stake of 12,658 shares — an estimated $94K sold.

Marshall Wace North America first reported a position in PACB in Q4 2018 and held it in 1 quarter. The position peaked at $94K in Q4 2018. 160 funds tracked by Wall St. Rank hold PACB as of Q1 2019.

  • Marshall Wace North America reported no remaining Pacific Biosciences position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace North America sold 12,658 Pacific Biosciences shares in Q1 2019, an estimated $94K.
  • Marshall Wace North America first reported a position in Pacific Biosciences in Q4 2018 and held it in 1 quarter.
  • Marshall Wace North America's Pacific Biosciences position peaked at $94K in Q4 2018.
  • 160 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.